TY - JOUR
T1 - Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers
AU - Xie, Dong
AU - Marks, Randolph
AU - Zhang, Mingrui
AU - Jiang, Gening
AU - Jatoi, Aminah
AU - Garces, Yolanda I.
AU - Mansfield, Aaron
AU - Molina, Julian
AU - Yang, Ping
N1 - Funding Information:
The work was supported by the USA National Institutes of Health Grants (R03 CA77118, R01 CA80127, R01 CA84354, and R01CA115857) and Mayo Clinic Foundation, Foundation for Youths of Shanghai Municipal Health Bureau (2012093), and Shanghai Hospital Development Center Grant (Grant No. shdc12012111).
Publisher Copyright:
Copyright © 2015 by the International Association for the Study of Lung Cancer.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Background: We sought to build prognostic nomograms and identify novel prognostic factors in small-cell lung cancer (SCLC) incorporating both clinical data and peripheral blood markers. Methods: We analyzed 938 patients with SCLC (555 extensive stage SCLC [ES-SCLC] and 383 limited stage SCLC [LS-SCLC]) diagnosed between 1997 and 2012 from a single institution. We investigated the prognostic value of pretreatment neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, red cell distribution width, hemoglobin, and other clinicopathological factors. Cox proportional hazards models determined the effects of multiple factors on overall survival (OS). Two nomograms were developed to predict median survival and 6- and 12-month OS for ES-SCLC, and 1- and 2-year OS for LS-SCLC. Results: In ES-SCLC, the multivariate Cox model identified neutrophil to lymphocyte ratio and red cell distribution width as significant prognostic factors for OS independent of age, Eastern Cooperative Oncology Group performance score, chest radiation, chemotherapy, liver metastases, and numbers of metastatic sites. In LS-SCLC, significant prognostic variables included platelet to lymphocyte ratio, age, smoking cessation, chest radiation, chemotherapy, surgery, and prophylactic cranial irradiation. The two nomograms show good accuracy in predicting OS, with a concordance index of 0.73 in both ES- and LS-SCLC. Conclusion: The two nomograms incorporating hematological markers could more accurately predict individualized survival probability of SCLC than the existing models.
AB - Background: We sought to build prognostic nomograms and identify novel prognostic factors in small-cell lung cancer (SCLC) incorporating both clinical data and peripheral blood markers. Methods: We analyzed 938 patients with SCLC (555 extensive stage SCLC [ES-SCLC] and 383 limited stage SCLC [LS-SCLC]) diagnosed between 1997 and 2012 from a single institution. We investigated the prognostic value of pretreatment neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, red cell distribution width, hemoglobin, and other clinicopathological factors. Cox proportional hazards models determined the effects of multiple factors on overall survival (OS). Two nomograms were developed to predict median survival and 6- and 12-month OS for ES-SCLC, and 1- and 2-year OS for LS-SCLC. Results: In ES-SCLC, the multivariate Cox model identified neutrophil to lymphocyte ratio and red cell distribution width as significant prognostic factors for OS independent of age, Eastern Cooperative Oncology Group performance score, chest radiation, chemotherapy, liver metastases, and numbers of metastatic sites. In LS-SCLC, significant prognostic variables included platelet to lymphocyte ratio, age, smoking cessation, chest radiation, chemotherapy, surgery, and prophylactic cranial irradiation. The two nomograms show good accuracy in predicting OS, with a concordance index of 0.73 in both ES- and LS-SCLC. Conclusion: The two nomograms incorporating hematological markers could more accurately predict individualized survival probability of SCLC than the existing models.
KW - Hematological markers.
KW - Neutrophil to lymphocyte ratio
KW - Nomogram
KW - Prediction model
KW - Small-cell lung cancer
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84942905355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942905355&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000585
DO - 10.1097/JTO.0000000000000585
M3 - Article
C2 - 26200277
AN - SCOPUS:84942905355
SN - 1556-0864
VL - 10
SP - 1213
EP - 1220
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 8
ER -